V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213409 | 20079857 | 1.8 | null | Curative (C) | 2018-04-10 | 2018-04-29 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101533681 |
| 20213410 | 20079858 | 1.66 | 66.7 | Palliative (P) | 2019-04-25 | 2019-05-21 | Trial Unspecified | 1 | N | TRIAL | 100651045 |
| 20213411 | 20079859 | 1.67 | 68.9 | Curative (C) | 2016-12-28 | 2017-01-06 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100307502 |
| 20213412 | 20079860 | 1.67 | 98.1 | Not known (9) | null | 2017-11-29 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101482213 |
| 20213413 | 20079861 | 1.75 | 71.4 | Adjuvant (A) | 2020-05-19 | 2020-06-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100033898 |
| 20213414 | 20079862 | 1.61 | null | Palliative (P) | 2018-04-19 | 2018-04-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100282934 |
| 20213415 | 20079863 | 1.73 | 87.6 | Curative (C) | 2018-12-07 | 2019-01-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100182408 |
| 20213417 | 20079864 | 1.83 | null | Neo-adjuvant (N) | 2018-07-15 | 2018-07-15 | IMATINIB | N | N | IMATINIB | 100018151 |
| 20213418 | 20079865 | 1.59 | 37.8 | Palliative (P) | 2019-07-27 | 2019-08-25 | Cape+Cisplatin+Trastuzumab Main | 02 | N | IMATINIB | 100486281 |
| 20213419 | 20079866 | 1.7 | 59.11 | Palliative (P) | 2020-01-13 | 2020-01-13 | Trial Unspecified | 01 | N | TRIAL | 101596587 |
| 20213420 | 20079867 | 1.75 | 72 | Palliative (P) | 2016-08-07 | 2016-08-11 | Trial Unspecified | 01 | N | TRIAL | 100487325 |
| 20213421 | 20079868 | 1.67 | 48.7 | Palliative (P) | 2017-09-18 | 2017-09-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100932326 |
| 20213422 | 20079869 | 1.65 | 59 | Neo-adjuvant (N) | 2018-12-19 | 2018-12-22 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100920495 |
| 20213423 | 20079870 | 1.69 | 64 | Neo-adjuvant (N) | 2015-01-27 | 2015-02-03 | Trial Unspecified | 01 | N | TRIAL | 100124449 |
| 20213424 | 20079871 | 1.5 | 113.8 | Curative (C) | 2017-10-10 | 2017-10-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101466472 |
| 20213425 | 20079872 | 1.58 | 56.8 | Palliative (P) | 2016-12-13 | 2016-12-14 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101149474 |
| 20213426 | 20079873 | 1.8 | 52 | null | 2019-01-05 | 2019-01-24 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100267610 |
| 20213427 | 20079874 | null | 77.8 | Palliative (P) | 2018-01-21 | 2018-01-27 | GO2 TRIAL | 02 | Y | TRIAL | 100602542 |
| 20213428 | 20079875 | 1.59 | 75.45 | null | 2021-08-09 | 2021-08-16 | LANREOTIDE | 02 | N | LANREOTIDE | 100763572 |
| 20213429 | 20079876 | 1.7 | 88.4 | Curative (C) | 2018-05-04 | 2018-05-09 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100219550 |
| 20213430 | 20079877 | null | 104.5 | null | 2016-10-16 | 2016-10-30 | HCX (Cape + Cisp + Tras) - Load | 02 | null | LANREOTIDE | 101724154 |
| 20213432 | 20079878 | 1.8 | 0 | Palliative (P) | 2018-12-12 | 2018-12-26 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100966642 |
| 20213434 | 20079879 | 1.87 | 71.2 | Palliative (P) | 2019-03-23 | 2019-04-08 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100998505 |
| 20213436 | 20079880 | 0 | 52.9 | Disease modification (D) | 2018-07-16 | 2018-08-27 | LANREOTIDE | 02 | N | LANREOTIDE | 101193171 |
| 20213437 | 20079881 | 1.67 | 83.5 | Palliative (P) | 2018-10-25 | 2018-10-25 | Trial Unspecified | 01 | N | TRIAL | 101178356 |
| 20213438 | 20079882 | 0 | 118.3 | null | 2019-10-25 | 2019-11-06 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 100005462 |
| 20213439 | 20079883 | null | 94.5 | Disease modification (D) | 2017-08-29 | 2017-09-03 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100772635 |
| 20213441 | 20079884 | 1.76 | 87 | Palliative (P) | 2018-01-10 | 2018-01-10 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101122118 |
| 20213442 | 20079885 | 1.81 | 81 | Palliative (P) | 2019-03-30 | 2019-03-30 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100296120 |
| 20213444 | 20079886 | 1.67 | 51.4 | Curative (C) | 2018-06-24 | 2018-07-19 | HCX (Cape + Cisp + Tras) - Main | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101651953 |
| 20213446 | 20079887 | 0 | 69.6 | Disease modification (D) | 2019-11-19 | 2019-12-01 | Cape+Cisplatin+Trastuzumab Main | 02 | N | LANREOTIDE | 101093521 |
| 20213447 | 20079888 | 1.73 | 86 | Palliative (P) | 2021-04-29 | 2021-05-28 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100199627 |
| 20213448 | 20079889 | 0 | 76 | Palliative (P) | 2016-06-02 | 2016-06-03 | Imatinib 400mg | 02 | N | IMATINIB | 100363062 |
| 20213449 | 20079890 | 1.64 | 67.35 | Neo-adjuvant (N) | 2021-07-07 | 2021-07-07 | Imatinib 400mg | 02 | N | IMATINIB | 100772052 |
| 20213450 | 20079891 | 1.61 | 59 | Palliative (P) | 2020-06-12 | 2020-06-27 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100002033 |
| 20213451 | 20079892 | 0 | null | Palliative (P) | 2017-04-30 | 2017-05-19 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100203670 |
| 20213452 | 20079893 | 1.58 | 66.5 | Palliative (P) | 2020-03-19 | 2020-03-19 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100213722 |
| 20213454 | 20079894 | 1.72 | 0 | Curative (C) | 2017-06-26 | 2017-07-01 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100597527 |
| 20213456 | 20079895 | 1.82 | 80.5 | Palliative (P) | 2017-08-05 | 2017-08-15 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100374260 |
| 20213457 | 20079896 | 1.92 | 65.6 | Curative (C) | 2016-08-24 | 2016-08-27 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100180843 |
| 20213458 | 20079897 | null | 67.8 | null | 2019-11-11 | 2020-02-06 | LANREOTIDE | 02 | N | LANREOTIDE | 100591865 |
| 20213460 | 20079898 | 1.8 | 65.6 | Curative (C) | 2019-01-19 | 2019-01-30 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101821807 |
| 20213462 | 20079900 | 1.87 | 73.6 | Palliative (P) | 2018-06-05 | 2018-06-25 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100467387 |
| 20213463 | 20079901 | 0 | null | Palliative (P) | 2018-11-06 | 2018-11-28 | HCX (Cape + Cisp + Tras) - Main | null | N | IMATINIB | 101186541 |
| 20213464 | 20079902 | 1.9 | 80.1 | Palliative (P) | 2018-02-28 | 2018-03-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101815671 |
| 20213465 | 20079903 | 1.45 | 42.1 | Palliative (P) | 2017-03-07 | 2017-03-21 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100019909 |
| 20213466 | 20079904 | 1.89 | 76 | null | 2016-07-16 | 2016-07-16 | Trial Unspecified | 01 | Y | TRIAL | 100906014 |
| 20213468 | 20079905 | null | 71 | Disease modification (D) | 2017-05-16 | 2017-06-01 | IMATINIB | 02 | N | IMATINIB | 100556610 |
| 20213469 | 20079906 | 1.76 | 83.6 | Palliative (P) | 2016-09-17 | 2016-09-25 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100484225 |
| 20213470 | 20079907 | 1.66 | 91.4 | Palliative (P) | 2018-06-23 | 2018-06-29 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100121648 |